Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.